So now we are 12 months behind the milestones advised at the 2020 AGM and the 20 Oct 2020 Presentation for the equity raising
I get as annoyed as anyone at slipping timelines but I’m not sure why you think that the program has slipped back by 12 months since October/November last year.
This is from the announcement today
Larger animal studies for VP-001 have commenced on schedule in Q2 2021 and will continue throughout Q3 2021
Subsequent to the GLP studies, PYC anticipates submitting an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in mid-2022 before commencing clinical development
And these were the milestones advised in the equity raising presentation and at the AGM last year
To me, it looks like the lead program is roughly a quarter behind. Of course, we are yet to see if a mid-2022 IND submission transpires.
PYC Price at posting:
15.5¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)